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Introduction
Currently, iodinated contrast media (ICM) are most 
common used drugs in radiology. Although exact data 
are unknown, an estimated number of several hundred 
million doses worldwide per year are administered with 
increasing frequency (1). This large number of ICM-
doses makes hypersensitivity reactions (HSRs) induced by 
ICMs a challenge in radiology, despite its low incidence 
of 0.004–3.0% (2,3). Upon its occurrence, immediate 
reactions (IRs) and non-immediate reactions (NIRs) should 
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be treated adequately. Following these reactions, patients 
with a history of a previous ICM-HSR are at higher risk 
to experience another adverse reaction following re-
exposure to contrast materials. Therefore, these patients 
require special prophylaxis (e.g., anti-allergic prophylaxis, 
antihistamines with or without glucocorticosteroids) before 
they can receive another ICM. 
Selection of an alternative ICM in an individual patient 
is another option, especially in those with a history of 
moderate reactions (in cases with severe reaction both 
ICM switch and premedication could be meaningful) 
(4,5). In the latter subgroup, a skin test can be helpful in 
the decision making process. ICMs producing a positive 
skin test should be avoided, but those exhibiting a negative 
skin test remain candidates for suitable subsequent ICM-
enhanced imaging. Sometimes, allergy testing [intradermal 
testing (IDT) as well as drug provocation tests (DPTs)] not 
only shows a reaction against the culprit compound but also 
against one or more other compounds. The literature calls 
this phenomenon “cross-reactivity” (6-17) or unspecific, 
irritative reactions (18). Although several papers deal with 
ICM ‘cross-reactivity’ (6-17), currently, the phenomenon is 
largely not understood and its clinical relevance is uncertain. 
This is particularly the central question of whether or not 
cross-reactivity should be considered when radiologists 
choose a non-culprit ICM in at-risk patients without a 
formal allergy workup. In this context, we tried to answer 
questions such as, which phenomenon “cross-reactivity” or 
individual reaction pattern plays the major role in clinical 
routine?” Therefore, the goal of the present study is to 
analyse systematically the phenomenon of ‘cross-reactivity’, 
and its clinical relevance.
Methods
Definition of cross-reactivity and polyvalent reactivity
Herein we focused on ICMs only, and used a definition 
that has been published (19). Briefly, skin tests displaying 
only one positive result are called monovalent reactivity. 
Skin tests showing two or more positive reactions across all 
ICM compounds are called polyvalent reactivity (formerly 
called “cross-reactivity”). Cross-reactivity (CR) is defined as 
multiple (two or more) positive test reaction within defined 
chemical ICM-groups (19). As mentioned previously, the 
following available and FDA-approved ICM compounds 
were grouped according to similarities of their chemical 
structures (19): iopentol, ioversol, iomeprol, iohexol, 
iodixanol, iosimenol, iopromide, iobitridol, iosarcol, 
iotrolan, amidotrizoate, ioxithalamate, and ioxaglate.
We need the differentiation between polyvalent 
reactivity and cross-reactivity, because the cross-reactivity 
does not depend on the iodine atom. In other words, the 
alleged “iodine allergy” does not exist (1,5). Moreover, the 
differentiation between polyvalent and cross-reactivity is 
one focus of our study.
We define as opposite to patients with cross-reactivity 
such with non-cross-reactivity or individual reaction 
pattern. The latter group is composed of patients with both 
monovalent reactivity, and polyvalent reactivity that does 
not fit into the cross-reactivity group.
Literature search criteria
Two investigators independently searched the online 
database PubMed from January 1995 until December 2019. 
The keywords “cross-reactivity”, “cross sensitivity”, “skin 
testing”, and “contrast media” were utilized in various 
combinations to find eligible articles. In addition, reference 
lists of relevant articles as well as the authors’ personal 
literature database were also scrutinized for other papers 
eligible for inclusion [papers from other sources (Figure 1)]. 
Full text research articles, short communications, case 
series (with more than three cases), and letters to the editor 
available online were included. Review articles, in vitro 
studies, studies focusing on gadolinium-based contrast 
agents, and animal studies were excluded. The search was 
limited to articles available in English.
Data extraction and study design 
Eligible publications were searched according to meta-
analysis criteria, but a formal meta-analysis was not 
performed. Two investigators independently extracted 
relevant data from each article. Discrepancies were resolved 
in consensus. The data extracted included the following 
information: name of the first author, year of publication, 
number of analyzed patients, number of patients showing 
polyvalent reactivity/cross-reactivity, type of hypersensitivity 
(IR or NIR), number of positive test reactions, and DPTs if 
performed.
Next, single published patients and their test results were 
re-evaluated. We documented the following data: age, sex, 
culprit ICM, tested ICMs and the results, and the type of 
HRS (IR or NIR). Patients with a minimum of one positive 
skin test reaction were extracted and pooled.
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Figure 1 Number of detected publications after PubMed database screening, and exclusion of non-relevant papers.
Statistical analysis
Demographic data, clinical characteristics, and test results 
were analyzed using descriptive statistics. The frequency of 
cross-reactivity/polyvalent reactions was calculated as the 
quotient of number of patients with multiple positive test 
reactions and the number of patients with positive test result.
The correlation coefficient (Spearman’s rho) was 
calculated to determine the correlation of number of tested 
ICMs and number of positive reactions.
For categorical data, Chi-squared or Fisher’s exact test was 
utilized. Continuous variables were expressed by mean and 
standard deviations (mean ± SD), and compared by Mann-
Whitney U test or the Student’s T-test. Odds ratios (ORs) 
and their 95% confidence intervals (95% CI) were calculated, 
and comparisons between different groups were made.
Sensitivity, specificity, positive predictive value (PPV), 
and negative predictive value (NPV), were analysed through 
the comparison of the chemical ICM-groupings (see also 
under ‘Chemical ICM-groups’ in the results section). We 
do not aim to analyse these parameters with respect to 
the gold standard, ICM re-exposure under radiological 
diagnostic conditions or by application the contrast medium 
in the context of a DPT.
We categorized the frequency of cross-reactivity/
polyvalent reactivity into not likely (<25%), less likely (25–
50%), likely (51–75%), and very likely (>75%).
P values of less than 0.05 were considered statistically 
significant. STATA software version 12.1 Inc., Chicago, IL, 
USA was utilized for statistical analysis.
Results
Study overview
Twenty-five articles published in 2001–2019 met the above-
mentioned inclusion criteria. We excluded 1,194 of 1,219 
identified publications, because their content did not fit into 
the study design or essential data were missing (Figure 1). A 
total pooled cohort of 2,444 patients presented in 25 papers 
comprised the study population. In 619 patients (25.3%), 
we documented positive skin test reactions. Nine studies 
focused on subjects with IR, ten on patients with NIR, and 
six studies on both IR and NIR (Table 1).
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Figure 2 Expected cross-reactivity. Among available/known ICMs (iodinated contrast media) due to their chemical structure expected cross-
reactivity is shown within black open rectangles. ICM, iodinated contrast medium.
            Cross-reac-
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Based on their similar chemical side chains, eight ICM-
groups were defined (Figure 2), including one large group 
consisting of seven ICMs, one small group consisting of 
two ICMs, and six groups consisting of only one ICM (19). 
The large group shares the N-(2,3-dihydroxypropyl)-
carbamoyl chemical moiety, and the small one the N-(2,3-
dihydroxypropyl)-N-methyl-carbamoyl moiety (Figure 3). 
The remaining six ICMs do not share chemical groups with 
other contrast agents (Figure 2).
Figure 4 shows the cross-reactivity classification of 
correct/false positive and negative reactions with respect to 
the culprits’ ICM grouping.
We hypothesized that ICM cross-reactions should 
preferentially occur within the defined groups. Inside the 
groups 582 (48.3%) and outside 246 (17.7%) of all skin tests 
were positive [P<0.0001; risk ratio 2.7 (95% CI: 2.4–3.1)] 
(Figure 5). The relative risk of an ICM cross-reaction within 
a chemically defined group was 2.7 times greater than 
between agents in other groups.
Re-evaluation of extracted patient data
Allergic subjects who were tested positively against ICMs 
and in whom individual skin test results were available from 
the literature were extracted. Of 619 reported patients 
with positive skin test reactions (Table 1), re-evaluation 
was possible in a subgroup of 340 patients. We excluded 
279 patients because of missing individual data or because 
the culprit ICM was unknown.
Patients had a mean age of 55 years (range, 7–93 years) 
and consisted of 85 men and 122 women (gender of 
133 patients was unknown). In 331 patients, a single ICM 
was the culprit for the reaction. In nine patients, two culprit 
ICM were identified. Two hundred eighteen (64.1%) patients 
had a history of an IR, 121 (35.6%) of a NIR, and one patient 
experienced a bi-phasic reaction with both IR and NIR.
The culprit-ICMs were positive tested in 289 cases 
(82.8%). Within the IR subgroup, 433 (27.5%) positive 
test results were obtained in 1,575 tested ICMs. The NIR 
subgroup had 363 (37.0%) positive test results, and 981 
ICMs were tested.
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Figure 3 Chemical structure of iohexol (above), and iobitridol (below) and the relevant chemical groups that share other ICMs too. ICM, 
iodinated contrast medium.
Correlation of tested ICMs
Of the 2,547 tested ICMs, 795 positive reactions (sensitivity 
0.31) could be detected. In order to find a possible 
dependency of the number of positive test reactions 
upon the number of tested ICMs we correlated these 
data (Spearmans rho), and found no statistical significant 
correlation (Figure S1).
Sensitivity and specificity
Based upon the chemical grouping in Figure 2, we identified 
580 positive and 622 negative test reactions within chemical 
groups, as well as 1,165 negative test results outside of the 
chemical groups, and positive reactions outside of chemical 
group could be found in 253 tests (Figure 6). These results 
led to sensitivity of 0.48, specificity 0.82, PPV 0.70, and 
NPV 0.65; OR 4.22 (95% CI: 3.5–5.0).
Frequency/incidence/risk
The incidence of cross-reactivity and polyvalent reactivity 
ranges from 0% to 100% (Table 1). The mean is 51.2%, and 
the median 50% for polyvalent reactions, and 42.3% and 
Figure 4 Overview of the decision making and classification of “correct positive”, “false positive”, “false negative” and “correct negative” 
cross-reactivity test reactions according to the structure-related chemical grouping of the ICMs (see Figure 2). ICM, iodinated contrast 
medium.
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Frequency of positive test reactions against
Culprit ICM Iohexol Iomeprol Iopentol Ioversol Iodixanol Iopromide Iobitridol Iopamidol Amidotrizoate Ioxaglate Ioxithalamate Iotrolan
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Figure 5 Frequencies of positive test reactions. Pairings and frequencies of positive test reactions against single ICMs (iodinated contrast 
media) with respect to the culprit ICM (iodinated contrast medium). Values in bold = result is lower (grey background: values should be 
>0.5) or higher (white background: values should be <0.5) than expected. ICM, iodinated contrast medium.
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Overall, the incidences of polyvalent reactivity are higher 
than incidences of cross-reactivity. The difference was 
statistically not significant.
Cross-reactivity was present in 7% to 75% (mean 32.4%) 
IR-patients of the extracted patient group and in 0% to 
100% (mean 55.1%) NIR-subjects (P<0.01).
According to the authors, 619 patients had positive 
reactions, and 262 (42.3%) had polyvalent reactions. 
Considering all tested ICMs of the re-evaluated group, 
polyvalent reactions were present in 178 (52.4%) cases. 
Following exclusion of positive reactions outside of 
chemical groups, 122 (35.8%) patients (127 reactions) 
remained with cross-reactivity (P<0.0001) (Table 2).
The comparison of the two subgroups cross-reactivity 
and non-cross-reactivity shows a dominance of the latter 
(Table 2). While IRs are more common in the non-cross-
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reactivity subgroup, NIRs dominate in the cross-reactivity 
subgroup (P<0.0001).
Crossover evaluation
Based on Figure 5, frequencies of positive reactions 
within of two reactivity-pairings (special culprit ICM 
and another ICM), and vice versa were built to test the 
hypothesis that the chemical structure could be responsible 
for the obtained test frequencies (crossover evaluation). 
For example, we compared the frequency of the reaction 
constellation iohexol (culprit)-iomeprol (reaction partner) 
with the frequency of iomeprol (culprit)-iohexol (reaction 
partner) (Figure 5). Since it should not matter which ICM 
is the culprit and which is the reaction partner, we defined 
equal or concordant reaction frequencies to be within 5% 
and differences in frequencies ≥6% to be not equal. We 
assessed 55 reaction-pairings. Five were excluded because 
of missing test results. Of the remaining 50 reaction-
pairings, concordance was established in 15 (30%) and not 
established in 35 (70%) cases.
Subgroup analyses
In the next step, we analysed subgroups with identical 
culprit ICM (Figure 7). Thereby, it became clear that the 
culprit ICM induced the highest incidence of positive test 
results. The obtained relative frequencies vary from 50% to 
100% (mean 84%).
The single results are presented in Figure 5. The greatest 
chemical group contains 36 single results. The constellation 
ioversol (as culprit ICM) and iopentol (as tested compound) 
is missing. In 23 single results the obtained frequency is 
lower than expected (bold numbers in Figure 5), and 12 
other single results show the expected frequencies. The 
small chemical group with iopromide and iobitridol shows 
twice too low values and twice expected frequencies. Three 
of the remaining four other chemical groups with only one 
ICM inside showed frequencies in expected dimensions, 
and once a too low value (Figure 5).
Results of ICM challenge tests
We identified 200 challenge tests in the literature. 
According to Figure 2 and the chemical group classification 
scheme, twenty tests were positive inside the chemical 
groups, 39 tests were negative inside the chemical groups, 
129 tests were negative outside the chemical groups, and 12 
tests were positive outside the chemical groups (Figure 8). 
Consequently, with respect to the chemical group 
classification the following parameters were calculated, the 
sensitivity of 0.34 (95% CI: 0.2241–0.4749), specificity 0.91 
Table 2 Comparison between patients with and without cross-reactivity
Variable Non cross-reactivity Cross-reactivity Significance (OR, 95% CI)
Frequency 222* (63.6%) 127* (36.4%) NS
Men/women 48**/77** 37**/45** NS
Mean age [range] 54.7 [7–93] 54.9 [19–80] NS
IR 160 62 <0.0001 (0.38, 0.24–0.59)
NIR 62 65
Number of tested ICMs 1,670 959 <0.0001 (0.24, 0.20–0.29)
Pos. tested ICMs 327 482
Culprit ICM positive tested 169 (76.1%) 120 (94.5%) <0.0001 (5.38, 2.36–12.23)
Pos inside chemical groups 190 (30.2%) 392 (68.8%) <0.0001 (0.2, 0.15–0.25)
Neg inside chemical groups 440 178
Pos outside chemical groups 152 (14.6%) 99 (26.2%) <0.0001 (0.48, 0.36–0.64)
Neg outside chemical groups 888 279
Comparison between patients showing cross-reactivity according to Figure 2 with those showing non cross-reactivity. *Sum >340, 
because nine pats had two culprit ICMs; **exclusion of unknown gender. OR, odds ratio; 95% CI, 95% confidence interval; IR, immediate 
reaction; NIR, non-immediate reaction; ICMs, iodinated contrast media; pos, positive; neg, negative.
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Figure 8 Results of drug provocation tests (DPTs) in the re-
evaluated patient group.
Figure 7 Subgroups with identical culprit ICM (mentioned on top), and the incidences of cross-reactivity (expected reactions = black), and 
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(95% CI: 0.8529–0.9533) (P<0.0001), OR 0.18 (95% CI: 
0.08–0.40), NPV 0.77 (95% CI: 0.6953–0.8279), and PPV 
0.625 (95% CI: 0.4375–0.7834).
Final evaluation
Based on the above presented results, in a final multi-step 
process, the likelihood of cross-reactivity or an individual 
reaction pattern (non-cross-reactivity) was evaluated.
(I) The correlation of tested ICMs with positive skin 
test reactions was assessed to determine whether 
ICM-test reactions are specific or unspecific (Figure 
S1). A correlation factor of r=0.05357 (P>0.05) was 
calculated for the extracted and re-evaluated patient 
group. These results indicate that the number 
of positive test results does not depend upon 
the number of tested ICMs. Therefore, rather a 
specific than nonspecific reactivity can be assumed.
(II) Next, the frequencies/incidences of both polyvalent 
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and cross-reactivity in the 25 clinical studies (8,10-
16,20-36) ranging from 0% to 100% (Table 1), 
also suggest an individual reaction pattern (non-
cross-reactivity) rather than a chemical structure 
dependent reactivity (cross-reactivity).
(III) Frequencies based on Figure 2 (cross-reactivity) 
are usually lower than frequencies among all 
available ICMs (polyvalent reactivity). The lower 
the difference between these values the more likely 
the cross-reactivity. We found in nine studies equal 
values for cross-reactivity and polyvalent, and in 12 
studies different values (Table 1).
(IV) Cross-over evaluation with identical reactivity-pairings 
in different roles (culprit ICM and another non-
culprit ICM) showed in 30% concordance, and in 70% 
discordance (Figure 5). This low value also supports the 
assumption of an individual reaction pattern.
(V) Although not significant, the phenomenon cross-
reactivity is less common than non-cross-reactivity 
(36.4 % versus 63.6%) (Table 2).
These results favour an individual reaction pattern, 
rather than a reactivity driven by chemical groups and so-
called cross-reactivity.
Discussion
This study for the first time presents in-depth analyses of 
the ‘cross-reactivity’ phenomenon in patients with ICM-
allergy. Available literature provides a correct definition of 
chemical groups responsible for ‘cross-reactivity’ (19), but 
lacks a critical analysis of its clinical relevance. Especially, 
the question as to whether ‘cross-reactivity’ or ‘non-cross-
reactivity’ plays the major role is of great clinical impact, 
because in patients at risk a well-tolerated non-culprit ICM 
even without an allergy test result should be found. This 
prompted us to analyse existing data from the literature to 
understand better the phenomenon called ‘cross-reactivity’.
Terminology
The correct use of terms is helpful in understanding the 
‘cross-reactivity’ phenomenon. Most papers dealing with 
this topic utilized no definition of the term, and referred to 
it synonymously with the term polyvalent positive reactions 
(3,8,26,30). However, this incorrectly implicates the 
iodine atom as being responsible for the reactivity, thereby 
resuscitating the old, incorrect concept of the “iodine 
allergy” (1,5).
Definition of chemical groups of ICMs
Although cross-reactivity depends on similar chemical 
groups, a clear definition is missing in most papers of the 
literature. The grouping described by Lerondeau et al. is 
confusing and it is uncertain how it was constructed (10).
This original paper for the first time used and identifies 
chemical groups (19) of the available ICMs as a basis for 
potential cross-reactivity (Figures 2,3). One large group 
consisting of iopentol, ioversol, iomeprol, iohexol, iodixanol, 
iosimenol, iopromide, and another smaller group consisting 
of iopromide and iobitridol cover the most clinically used 
ICMs. The difference between members of the two larger 
groups is minimal, comprising of a methyl group only 
(Figure 3). The remaining six ICMs iopamidol, iosarcol, 
iotrolan, amidotrizoate, ioxithalamate, and ioxaglate are 
soloists. This means they are not readily grouped together 
based on common chemical structures (Figure 2).
The proposed grouping appears to have some validity, 
because we found a statistically significant greater proportion 
of positive reactions within than outside of these groups 
(see Results under ‘Chemical groups’ and in Figure 5). On 
the other hand, the sensitivity of 0.48 for this classification 
scheme in the extracted and re-evaluated patient group shows 
that reactivity within the defined groups is not as frequent as 
suspected if the chemical group model were valid.
Frequency/incidence/risk
The overall frequency of polyvalent reactions (so called 
“cross-reactivity”) ranges from 0% to 100% (mean 53.2%) 
in the literature (8,10-16,20-36) (Table 1). Interestingly, only 
five (20%) papers clearly mention the identified frequency 
of polyvalent reactions as a percentage (8,10,13,24,34), 
while the others note the absolute number of patients 
showing “cross-reactivity”.
In general, the observed polyvalent and cross-reactions 
ranged from 0.0% to 100% (Table 1), supporting an 
individual reaction pattern rather than the influence of 
chemical structure similarities upon positive test results.
‘Cross-reactivity’ exists only in two groups as shown in 
Figure 2. Therefore, literature data was re-analyzed. The 
frequency of polyvalent reactivity is increased as compared 
to the frequency of cross-reactivity (Table 1).
Correlation of tested ICMs
Since no significant correlation was found between the 
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number of tested ICMs and positive test results (Figure S1), 
the results do not support an overall reactivity between all 
ICMs.
Polyvalent reactivity versus cross-reactivity
The assumption that all ICMs show cross-reactivity with 
each other is a propagation of the old, incorrect concept of 
the alleged “iodine allergy” (1,5). Although most authors 
deny the existence of “iodine allergy”, 20 papers were 
found that regard “cross-reactivity” as multiple positive test 
reactions throughout the entire group of ICMs (8,10-15,20-
24,26,28-31,33-35). The kind of definition influences the 
resulting data (Table 1).
Crossover evaluation
Frequencies of ICM pairings (culprit contrast medium A 
and positive reaction to contrast medium B and vice versa) 
should result in nearly equal values. For example, the 
frequencies of the following pairings:
	 Iobitridol (culprit) AND iopromide (reaction 
partner);
	 Iopromide (culprit) AND iobitridol (reaction 
partner).
should be identical. Surprisingly, in most instances 
(70%) such results did not occur which likewise suggests 
an individual reaction pattern underlying the obtained 
frequencies, and not reactions driven by chemical structure 
similarities of the tested ICMs.
DPT
DPTs are used to verify a positive or a negative IDT 
result. DPTs are necessary in the diagnosis of drug HSRs 
when skin reaction tests are considered insensitive (37). 
In the extracted patient group, 200 DPTs were reported 
(8,10,11,15,16,20-22,26-29,31,36). Most provocations were 
negative, and only a small proportion were false positive. 
This means that testing physicians/allergists generally 
chose the correct (i.e., tolerated) ICMs for the challenge 
testing. Since the ICM-grouping presented herein (Figure 2) 
was unknown to them, this decision-making process was 
not biased. A sensitivity of 0.34 and a specificity of 0.91 
[P<0.0001; OR (95% CI): 0.18 (0.08–0.40)] was calculated. 
Consequently, the sensitivity of DPT is lower than the 
sensitivity of IDTs when cross-reactivity is regarded (0.48), 
and only slightly decreased when polyvalent reactivity is 
considered (0.32).
Limitations
The study has the following limitations. Since we extracted 
data from the literature, not all published patients could 
be re-evaluated; data from 279 patients were missing. The 
general problem of insufficient documentation (38) not 
only hinders efficient management of patients undergoing 
radiological routine procedures, but also scientific analyses. 
Another limitation is the relative low number of re-
evaluated cases. Therefore, further analyses in greater 
patient groups are necessary.
Broad ranges of other limitations—influencing the 
skin test accuracy—do also exist. These are, the loss of 
sensitivity of skin tests over time, including the lack of 
documenting the diagnostic delay between reaction and 
skin test, the lack of uniform test protocols (most use 
1:10 dilution, but some use undiluted ICM which may 
improve sensitivity but also perhaps increase false positive, 
irritative reactions), the lack of standardized test panels, 
the uncertainty of the clinical relevance of positive skin 
tests, and the missing differentiation between immediate 
and nonimmediate HSRs. In many cases, the culprit ICM 
was unknown; therefore, we excluded a great number of 
published cases.
Conclusions
Taken together, the herein provided data show that it is 
necessary to define ICM groups as the basis for potential 
cross-reactivity. Without definition or limitation to a 
group of potential reaction partners, all available ICMs are 
included, and this implicates that “cross-reactivity” would 
only replace the old term “iodine allergy” without changing 
underlying facts or practice.
Given the herein obtained results (e.g., the incidence 
of “cross-reactivity” ranging from 0% to 100%), it seems 
likely that an individual reaction pattern plays a major role 
by influencing the frequencies of multiple positive test 
reactions rather than similarities of the chemical ICM-
structure, and thereby, so-called cross-reactivity.
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Figure S1 Correlation between number of tested iodinated contrast media and number of positive tested iodinated contrast media in the 
extracted patient group. Spearman’s rho =0.05357; P>0.05.
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